All In Biotech

Drug Trial Radar · NCT06932536

The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Formulation F1) in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Phase I Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of SR750 (Formulation F1) in Chinese Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Apr 28, 2025

Primary completion

Jul 7, 2025

Study completion Jul 7, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, safety and tolerability of SR750 (formulation F1) in Chinese healthy subjects.

Conditions

  • Healthy

Interventions

  • SR750 tabletDrug

    Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally

  • PlaceboDrug

    Ascending single and multiple doses of placebo orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Up to 48 hours post-dose
  2. TmaxTime frame: Up to 48 hours post-dose
  3. AUCTime frame: Up to 48 hours post-dose
  4. CL/FTime frame: Up to 48 hours post-dose
  5. t1/2Time frame: Up to 48 hours post-dose
  6. RacTime frame: Up to 48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.